ClinicalTrials.gg
CompletedNCT04617028Updated Nov 13, 2023

Jaktinib Versus Hydroxycarbamide in Subjects With Intermediate-2 or High-risk Myelofibrosis

A Phase 3 interventional study of Jaktinib and Placebo to match Hydroxycarbamide in Myelofibrosis, sponsored by Suzhou Zelgen Biopharmaceuticals Co.,Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-11-13.

Sponsored by Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
105
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing jaktinib in Primary Myelofibrosis — 4 open to participants now, 4 under way, none of them phase 3. jaktinib · Primary Myelofibrosis.

Enrollment
2nd of 10
105 · median 37
Started
2021
with 2 others
Phase 3
Only one
of the 10
Registered
3rd of 10
by date
Lead sponsor
7 of 10
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Among the 10 studies testing jaktinib in Primary Myelofibrosis, this one is the 2nd largest by enrollment, is one of 3 that started in 2021, is the only one in phase 3, and was the 3rd registered.

Primary Myelofibrosis

627 studies on the registry are indexed under Primary Myelofibrosis; 126 are open to participants now.

Browse Primary Myelofibrosis studies →

Open to participants now

4 of the 10 studies testing jaktinib in Primary Myelofibrosis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

About jaktinib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 102 Primary Myelofibrosis studies recruiting now, 84 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing jaktinib in Primary Myelofibrosis, or all of them as a file.
02

Study summary

This study is to determine the efficacy of Jaktinib versus Hydroxycarbamid in participants with Intermediate-2 or High-risk myelofibrosis

03

Conditions studied

  • Myelofibrosis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years old,either male or female;
  • Subjects diagnosed with a PMF according to World Health Organiztion criteria (2016 Edition), or patients diagnosed with a Post-PV-MF or Post-EF-MF according to International Working Group for Myeloproliferative Neoplasms Research and Treatment criteria;
  • High risk or intermediate-2 risk as defined by the Dynamic International Prognostic Scoring System (DIPSS) for Primary Myelofibrosis;
  • Subjects have no plan for stem cell transplantation in the near future;
  • of > 24 weeks;
  • performance status of 0-1;
  • Palpable splenomegaly at least 5 cm below left costal margin;
  • Peripheral blood blast count ≤ 10%;
  • Subjects who have not yet received treatment with a JAK inhibitor, or Subjects who have been treated with JAK inhibitors for ≤10 days;
  • Subjects have not received growth factor, thrombopoietin mimetics or transfusion(s) within 2 weeks before the randomization; ≥ 1.0×10\^9/L, platelet count ≥ 100×10\^9/L within 2 days before the randomization;
  • Normal functions in major organs within 7 days before the randomization, fulfilling the following criteria: and AST ≤ 2.5×; DBIL and ≤ 2.0×ULN; serum creatinine ≤ 1.5×ULN;
  • If the subject is receiving any anti-myelofibrosis treatment (except for JAK inhibitors and hydroxyurea) at screening, the dosing regimen must remain unchanged for at least 2 weeks before screening. If the investigator judges that there is no need to continue to use, stop the use of thalidomide, androgens and prednisone> 10 mg during screening. The drugs used to improve anemia should be stopped for at least 6 half-lives or 2 weeks before randomization(whichever is the longer);
  • If the subject is receiving Hydroxycarbamide treatment at screening, the drug must be discontinued ≥ 2 weeks before the randomization;
  • Meet the requirements of the ethics committee and willing to sign the form;
  • Ability to comply with trial and follow-up procedures.

Exclusion criteria

Exclusion Criteria:

  • Subjects with any significant clinical and laboratory abnormalities which may affect the safety evaluation, such as uncontrolled diabetes, uncontrolled hypertension after taking two or more hypotensive drugs, peripheral neuropathy;
  • Subjects with congestive heart failure, uncontrolled or unstable angina or myocardial infarction, cerebrovascular accident, or pulmonary embolism within 24 weeks prior to screening;
  • Subjects who have not fully recovered from surgical operation within 4 weeks prior to screening;
  • Subjects suffering from arrhythmia and requiring treatment at screening;
  • Subjects with clinical symptoms of active bacterial, viral, parasitic or fungal infections requiring treatment at screening;
  • Chest X-rays suggest an active lung infection at screening;
  • Subjects who had active tuberculosis infection within 48 weeks before screening;γ-Interferon release test suggests latent tuberculosis infection at screening;
  • Subjects who had undergone splenectomy, or received radiotherapy to the spleen within 48 weeks before screening;
  • Subjects with known (HIV), known active infectious (HepB), and/or known active infectious (HepC);
  • Subjects with epilepsy or patients who have received psychotropic drug or sedatives during screening;
  • Female subjects who are pregnant, currently breastfeeding, planning to become pregnant;Subjects who are unable to adopt effective methods during the study; Male subjects who did not use condoms during the dosing period and within 2 days after the last dose
  • Subjects who had experienced malignant tumors within the past 5 years (except for adequately treated local basal cell carcinoma of the skin and cervical carcinoma in situ that have been cured);
  • Subjects who are unsuitable to the trial in combination with other serious diseases, as identified by the investigator;
  • Subjects with suspected allergies to Jaktinib or its ;
  • Subjects who have participated in another clinical trial of a new drug or medical instrument within 12 weeks before screening.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
105 participants (actual)

Study arms

  • Experimental
    Jaktinib

    Participants will receive Jaktinib plus placebo to match Hydroxycarbamide.

    Drug: Jaktinib · Drug: Placebo to match Hydroxycarbamide

  • Active comparator
    Hydroxycarbamide

    Participants will receive Hydroxycarbamide plus placebo to match Jaktinib.

    Drug: Hydroxycarbamide Tablets · Drug: Placebo to match Jaktinib

Interventions

  • Jaktinib Hydrochloride Tablets administered orally twice daily

  • DrugPlacebo to match Hydroxycarbamide

    Placebo to match Hydroxycarbamide Tablets administered orally twice daily

  • Hydroxycarbamide Tablets administered orally twice daily

  • DrugPlacebo to match Jaktinib

    Placebo to match Jaktinib Tablets administered orally twice daily

06

What researchers measure

Primary outcomes

  1. Splenic response rate at Week 24

    Splenic response rate at Week 24 is defined as the proportion of participants achieving a ≥ 35% reduction in spleen volume at Week 24 from baseline as measured by MRI or CT

    Time frame: Week 24

Secondary outcomes

  1. Proportion of transfusion dependent patients converted to non-transfusion dependent patients at baseline

    Time frame: From start of drug administration up to 7 days after last dose of study treatment

07

Study locations

1 site
  • The First Affiliated Hospital of Medical School of Zhejiang University
    Hangzhou, Zhejiang 310003, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in Oct 2023, 32 months.

Of 22 phase 3 interventional studies under Primary Myelofibrosis, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 68. This study's 32 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2020
First posted
Nov 5, 2020
StartActual
Feb 5, 2021
Primary completionActual
Oct 18, 2023
CompletionActual
Oct 18, 2023
Last update
Nov 13, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04617028
Responsible party
Sponsor
First posted
Nov 5, 2020
Start date
Feb 5, 2021
Primary completion
Oct 18, 2023
Completion
Oct 18, 2023
Last update
Nov 13, 2023

Study contacts

Jie Jin, PhD
principal investigator · The First Affiliated Hospital of Medical School of Zhejiang University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Jaktinib

Start the discussion